A systematic review by Vener et al. found that imatinib is often preferred in patients with comorbidities since most of its adverse effects, such as weight gain from fluid retention, muscle pain, and rashes, are, in most instances, easily manageable and temporary [22]. However, as many as 35% of CML patients will discontinue imatinib due to lack of efficacy, intolerance, or developed resistance by the tumor, usually by mutations occurring in the BCR-ABL kinase domain [10]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.